We further demonstrated the tumor growth inhibition and anti-angiogenesis effects of emodin on pancreatic cancer in vivo, with downregulating the expression of NF-κB and NF-κB-regulated proteins (i.e. VEGF, MMP-2, MMP-9, and eNOS) and with roles in angiogenesis inhibition and reducing eNOS phosphorylation. The gene discussed is MMP2; the disease is familial pancreatic carcinoma.